These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 22753872)

  • 1. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations.
    Will B; Zhou L; Vogler TO; Ben-Neriah S; Schinke C; Tamari R; Yu Y; Bhagat TD; Bhattacharyya S; Barreyro L; Heuck C; Mo Y; Parekh S; McMahon C; Pellagatti A; Boultwood J; Montagna C; Silverman L; Maciejewski J; Greally JM; Ye BH; List AF; Steidl C; Steidl U; Verma A
    Blood; 2012 Sep; 120(10):2076-86. PubMed ID: 22753872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perturbed hematopoietic stem and progenitor cell hierarchy in myelodysplastic syndromes patients with monosomy 7 as the sole cytogenetic abnormality.
    Dimitriou M; Woll PS; Mortera-Blanco T; Karimi M; Wedge DC; Doolittle H; Douagi I; Papaemmanuil E; Jacobsen SE; Hellström-Lindberg E
    Oncotarget; 2016 Nov; 7(45):72685-72698. PubMed ID: 27683035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement and functional impairment of the CD34(+)CD38(-)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8.
    Nilsson L; Astrand-Grundström I; Anderson K; Arvidsson I; Hokland P; Bryder D; Kjeldsen L; Johansson B; Hellström-Lindberg E; Hast R; Jacobsen SE
    Blood; 2002 Jul; 100(1):259-67. PubMed ID: 12070035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coexistence of aberrant hematopoietic and stromal elements in myelodysplastic syndromes.
    Abbas S; Kini A; Srivastava VM; M MT; Nair SC; Abraham A; Mathews V; George B; Kumar S; Venkatraman A; Srivastava A
    Blood Cells Mol Dis; 2017 Jul; 66():37-46. PubMed ID: 28822917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine.
    Miltiades P; Lamprianidou E; Vassilakopoulos TP; Papageorgiou SG; Galanopoulos AG; Kontos CK; Adamopoulos PG; Nakou E; Vakalopoulou S; Garypidou V; Papaioannou M; Hatjiharissi E; Papadaki HA; Spanoudakis E; Pappa V; Scorilas A; Tsatalas C; Kotsianidis I;
    Clin Cancer Res; 2016 Apr; 22(8):1958-68. PubMed ID: 26700206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cytogenetic characteristics of hematopoietic and stromal progenitor cells in myelodysplastic syndrome].
    Pimenova MA; Parovichnikova EN; Kokhno AV; Domracheva EV; Manakova TE; Mal'tseva IuS; Konnova ML; Shishigina LA; Savchenko VG
    Ter Arkh; 2013; 85(7):34-42. PubMed ID: 24137945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal Analysis of DNA Methylation in CD34+ Hematopoietic Progenitors in Myelodysplastic Syndrome.
    Wong YF; Micklem CN; Taguchi M; Itonaga H; Sawayama Y; Imanishi D; Nishikawa S; Miyazaki Y; Jakt LM
    Stem Cells Transl Med; 2014 Oct; 3(10):1188-98. PubMed ID: 25122688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level.
    Nilsson L; Astrand-Grundström I; Arvidsson I; Jacobsson B; Hellström-Lindberg E; Hast R; Jacobsen SE
    Blood; 2000 Sep; 96(6):2012-21. PubMed ID: 10979941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q.
    Zhou L; Opalinska J; Sohal D; Yu Y; Mo Y; Bhagat T; Abdel-Wahab O; Fazzari M; Figueroa M; Alencar C; Zhang J; Kambhampati S; Parmar S; Nischal S; Hueck C; Suzuki M; Freidman E; Pellagatti A; Boultwood J; Steidl U; Sauthararajah Y; Yajnik V; McMahon C; Gore SD; Platanias LC; Levine R; Melnick A; Wickrema A; Greally JM; Verma A
    J Biol Chem; 2011 Jul; 286(28):25211-23. PubMed ID: 21532034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytogenetic analysis of CD34+ subpopulations in AML and MDS characterized by the expression of CD38 and CD117.
    Haase D; Feuring-Buske M; Schäfer C; Schoch C; Troff C; Gahn B; Hiddemann W; Wörmann B
    Leukemia; 1997 May; 11(5):674-9. PubMed ID: 9180291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MDS: roadblock to differentiation.
    Agarwal A
    Blood; 2012 Sep; 120(10):1968-9. PubMed ID: 22956526
    [No Abstract]   [Full Text] [Related]  

  • 12. Recurrent Abnormal Clones in Myelodysplastic Syndrome Marrow Originate from Cells at a Pluripotent Stem Level and Maintain Their Early Differentiation Potency.
    Qi H; Qingxia Z; Xiao L; Lingyun W; Feng X; Zheng Z; Chunkang C
    Cancer Invest; 2015; 33(8):369-77. PubMed ID: 26135215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDS/AML-associated cytogenetic abnormalities in multiple myeloma and monoclonal gammopathy of undetermined significance: evidence for frequent de novo occurrence and multipotent stem cell involvement of del(20q).
    Nilsson T; Nilsson L; Lenhoff S; Rylander L; Astrand-Grundström I; Strömbeck B; Höglund M; Turesson I; Westin J; Mitelman F; Jacobsen SE; Johansson B
    Genes Chromosomes Cancer; 2004 Nov; 41(3):223-31. PubMed ID: 15334545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moleculary Confirmed, Cytogenetic Remission in a Case with Myelodysplastic Syndrome Treated with Azacitidne.
    Panovska-Stavridis I; Ivanovski M; Trajkova S; Pivkova-Veljanovska A; Popova-Labaceska M; Matevska-Geshovska N; Noveski P; Plaseska-Karanfilska D; Cevreska L; Dimovski AJ
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2017 Dec; 38(3):157-162. PubMed ID: 29668469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesenchymal stem cells in myelodysplastic syndromes: phenotypic and cytogenetic characterization.
    Flores-Figueroa E; Arana-Trejo RM; Gutiérrez-Espíndola G; Pérez-Cabrera A; Mayani H
    Leuk Res; 2005 Feb; 29(2):215-24. PubMed ID: 15607371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorescence in situ hybridization of progenitor cells obtained by fluorescence-activated cell sorting for the detection of cells affected by chromosome abnormality trisomy 8 in patients with myelodysplastic syndromes.
    Saitoh K; Miura I; Takahashi N; Miura AB
    Blood; 1998 Oct; 92(8):2886-92. PubMed ID: 9763574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes.
    Pang WW; Pluvinage JV; Price EA; Sridhar K; Arber DA; Greenberg PL; Schrier SL; Park CY; Weissman IL
    Proc Natl Acad Sci U S A; 2013 Feb; 110(8):3011-6. PubMed ID: 23388639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitation of minimal residual disease in acute myelogenous leukemia and myelodysplastic syndromes in complete remission by molecular cytogenetics of progenitor cells.
    Engel H; Drach J; Keyhani A; Jiang S; Van NT; Kimmel M; Sanchez-Williams G; Goodacre A; Andreeff M
    Leukemia; 1999 Apr; 13(4):568-77. PubMed ID: 10214863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and hematopoietic potential of CD45- clonal cells with very immature phenotype (CD45-CD34-CD38-Lin-) in patients with myelodysplastic syndromes.
    Ogata K; Satoh C; Tachibana M; Hyodo H; Tamura H; Dan K; Kimura T; Sonoda Y; Tsuji T
    Stem Cells; 2005 May; 23(5):619-30. PubMed ID: 15849169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes.
    Chesnais V; Arcangeli ML; Delette C; Rousseau A; Guermouche H; Lefevre C; Bondu S; Diop M; Cheok M; Chapuis N; Legros L; Raynaud S; Willems L; Bouscary D; Lauret E; Bernard OA; Kosmider O; Pflumio F; Fontenay M
    Blood; 2017 Jan; 129(4):484-496. PubMed ID: 27856460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.